Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $112.58 Analyst target: $193.95 Upside: 72.28%
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
See the full interactive analysis & chart →Informational only — not investment advice.